HPV vaccination in women aged 24-45 years

The Lancet

Volumn 374, Issue 9697, 2009, Pages 1239-

  Solomon, Diane ^a   Castle, Phil ^a   Hildesheim, Allan ^a   Katki, Hormuzd A ^a   Schiffman, Mark ^a   Wacholder, Sholom ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

DRUG EFFICACY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; LETTER; PRIORITY JOURNAL; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; WART VIRUS; ADULT; FEMALE; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; NOTE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; VACCINATION;

EID: 70349974985     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61782-7     Document Type: Letter

References (3)

1. Muñoz N., Manalastas R., Pitisultithum P., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373 (2009) 1949-1957
2. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and CIN2/3: critical role of duration of infection. J Natl Cancer Inst (in press).
3. Castle P.E., Fetterman B., Akhtar I., et al. Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol 114 (2009) 365-369